A potential clinical scenario for use of combined LSD1 and mTORC1 inhibition is to promote differentiation of residual clonogenic AML cells in a minimal residual disease setting after, for example, completion of intensive chemotherapy. Here, KDM1A is linked to acute myeloid leukemia.